Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety
- PMID: 27851918
- DOI: 10.1016/j.immuni.2016.10.015
Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety
Abstract
Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent clinical antitumor effects in a variety of blood cancers. However, clinical activity in solid tumors has been disappointing and toxicity has been a serious concern (Lamers et al., 2013; Morgan et al., 2010). We recently found that a CAR composed of a scFv antibody fragment specific for the Tn-glycoform of MUC1 had potent activity in preclinical models of blood cancer and adenocarcinoma (Posey et al., 2016).
Copyright © 2016. Published by Elsevier Inc.
Comment in
-
Killer ILCs in the Fat.Immunity. 2017 Feb 21;46(2):169-171. doi: 10.1016/j.immuni.2017.02.004. Immunity. 2017. PMID: 28228274
Comment on
-
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014. Immunity. 2016. PMID: 27332733 Free PMC article.
-
Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells.Immunity. 2016 Nov 15;45(5):945-946. doi: 10.1016/j.immuni.2016.10.014. Immunity. 2016. PMID: 27851917
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous